



(11) **EP 2 699 906 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
29.11.2017 Bulletin 2017/48

(21) Application number: **12773652.8**

(22) Date of filing: **16.04.2012**

(51) Int Cl.:
G01N 33/533^(2006.01) G01N 33/543^(2006.01)

(86) International application number:
PCT/US2012/033808

(87) International publication number:
WO 2012/145270 (26.10.2012 Gazette 2012/43)

(54) **LUMINESCENT POLYMER CYCLIC AMPLIFICATION**

CYCLISCHE AMPLIFIKATION LUMINESZENTER POLYMERE

AMPLIFICATION CYCLIQUE DE POLYMÈRE LUMINESCENT

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **20.04.2011 US 201161477171 P**

(43) Date of publication of application:
26.02.2014 Bulletin 2014/09

(73) Proprietor: **Access Medical Systems, Ltd.**
Palo Alto, CA 94303 (US)

(72) Inventors:
• **ZUK, Robert F.**
Palo Alto, CA 94303 (US)
• **TAN, Hong**
Palo Alto, CA 94303 (US)

(74) Representative: **Moore, Michael Richard et al**
Keltie LLP
No.1 London Bridge
London SE1 9BA (GB)

(56) References cited:
EP-A1- 0 522 677 WO-A1-92/08979
WO-A1-2009/126249 WO-A2-2010/101931
US-A1- 2003 124 595 US-A1- 2006 127 942
US-A1- 2007 034 529 US-B1- 6 399 397

• **BLACKBURN G F ET AL:**
"ELECTROCHEMILUMINESCENCE DETECTION FOR DEVELOPMENT OF IMMUNOASSAYS AND DNA PROBE ASSAYS FOR CLINICAL DIAGNOSTICS", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 37, no. 9, 1 September 1991 (1991-09-01), pages 1534-1539, XP000232533, ISSN: 0009-9147

EP 2 699 906 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**FIELD OF THE INVENTION**

5 [0001] The invention relates to a method for detecting an analyte in a liquid sample using a probe having a small surface and a branched polymer having multiple binding molecules and multiple fluorescent or chemiluminescent labels. The sensitivity of the method is improved by cycling the binding reaction and amplification reaction several times.

BACKGROUND OF THE INVENTION

10 [0002] In many immunoassays applications it is desirable to develop high sensitivity detection methods. Luminescent dyes, emitting either fluorescent or chemiluminescent signals, offer several practical advantages, i.e. stability, low cost, amenable to labeling procedures and spectral properties with minimal interference from biological samples or solid phase substrates. Fluorescent dyes have a disadvantage compared to other detection methods, particularly ELISA, where enzyme activity amplifies the amount of detectable signal associated with immune complex formation.

15 [0003] Arylsulfonate cyanine fluorescent dyes are described in Mujumdar et al. (1993) Bioconjugate Chemistry, 4:105-111; Southwick et al. (1990) Cytometry, 11:418-430; and U.S. Pat. No. 5,268,486. Cy5 is described in each of the references and is commercially available from Biological Detection Systems, Inc., Pittsburgh, Pa., under the trade-name FLUOROLINK™ Cy5™. The arylsulfonate cyanine fluorescent dyes have high extinction coefficients (typically
20 from 130,000 L/mole to 250,000 L/mole), good quantum yields, fluorescent emission spectra in a range (500 nm to 750 nm) outside of the autofluorescence wavelengths of most biological materials and plastics, good solubilities, and low non-specific binding characteristics.

[0004] Despite these excellent properties, arylsulfonate cyanine fluorescent dyes suffer from certain limitations. In particular, these dyes have a relatively narrow Stokes shift which results in significant overlap between the excitation and emission spectra of the dye. The overlap of excitation and emission spectra, in turn, can cause self-quenching of the fluorescence when the dye molecules are located close to each other when excited. Such self-quenching limits the number of arylsulfonate dye molecules which can be conjugated to a single antibody molecule for use in immunoassays. In the case of Cy5, an exemplary arylsulfonate cyanine fluorescent dye, the Stokes shift is 17 nm (which is the difference between an excitation wavelength of 650 nm and an emission wavelength of 667 nm). Optimal fluorescent yield is
25 obtained when from two to four Cy5 molecules are conjugated to a single antibody molecule. The fluorescent signal output drops rapidly when more than four dye molecules are conjugated to a single antibody molecule. The inability to conjugate more than four dye molecules to individual antibody molecules significantly limits the sensitivity of immunoassays using Cy5-labelled antibodies and other binding substances.

[0005] U.S. Publication 2001/0312105 discloses a detection system and fluorescent immunoassays. Document WO
30 2010/101931 A2 discloses a luminescent immunoassay for detecting an analyte in a liquid sample. These publications do not disclose amplification by cycling the probe back and forth in the reagent vessel and the amplification vessel.

[0006] There is a need for an improved method for detecting analytes with high sensitivity by fluorescent or chemiluminescent immunoassay. The method should be easy to handle by the users and should provide high specific signal and minimal background noise.

SUMMARY OF INVENTION

[0007] The present invention is directed to a luminescent immunoassay method for detecting an analyte in a liquid sample with high sensitivity. The method comprises the steps of: (a) obtaining a probe having a first antibody immobilized
35 on the tip of the probe, wherein the diameter of the tip surface is ≤ 5 μ m; (b) dipping the probe tip into a sample vessel containing a sample solution having an analyte to bind the analyte to the first antibody on the probe tip; (c) dipping the probe tip into a reagent vessel containing a reagent solution comprising a reagent of a second antibody conjugated with a first member of a binding pair to bind the reagent to the analyte; (d) dipping the probe tip into a first washing vessel containing a first wash solution to wash the probe tip; (e) dipping the probe tip into an amplification vessel containing
40 an amplification solution comprising a polymer conjugated with at least 5 molecules of second member of the binding pair and at least 25 luminescent labels, to form an immunocomplex of the analyte, the first antibody, the second antibody, and the first and the second members of the binding pair on the probe tip, wherein the polymer is branched and has a molecular weight of at least 1 million daltons, and the luminescent labels have a molecular weight of less than 2,000 Daltons; (f) dipping the probe tip into a second washing vessel containing a second wash solution to wash the probe tip; (g) repeating steps (c) to (f) 1-10 times, and (g) detecting the immunocomplex formed by measuring the luminescent
45 signal on the probe tip; wherein the first antibody and the second antibody are antibodies against the analyte.

BRIEF DESCRIPTION OF THE DRAWINGS**[0008]**

- 5 FIG. 1 illustrates an optical detecting system for detecting fluorescent signal from the sensing surface of the probe.
 FIG. 2 illustrates an electrochemiluminescent detecting system for detecting chemiluminescent signal on the probe tip.
 FIG. 3 illustrates an immunoassay format for detecting an antigen analyte. Ab: antibody, Ag: antigen, Sa: streptavidin, B: biotin, F: fluorescent label.
 10 FIG. 4 illustrates probe transfer in cyclic amplification.
 FIG. 5 shows a flow chart of the preparation crosslinked ficoll 400-SPDP.

DETAILED DESCRIPTION OF THE INVENTION**15 Definitions**

[0009] Terms used in the claims and specification are to be construed in accordance with their usual meaning as understood by one skilled in the art except and as defined as set forth below.

[0010] "About," as used herein, refers to within $\pm 10\%$ of the recited value.

20 **[0011]** An "analyte-binding molecule", as used herein, refers to any molecule capable of participating in a specific binding reaction with an analyte molecule.

[0012] An "aspect ratio" of a shape refers to the ratio of its longer dimension to its shorter dimension.

[0013] A "binding molecular," refers to a molecule that is capable to bind another molecule of interest.

25 **[0014]** A "binding pair," as used herein, refers to two molecules that are attracted to each other and specifically bind to each other. Examples of binding pairs include, but not limited to, an antigen and an antibody against the antigen, a ligand and its receptor, complementary strands of nucleic acids, biotin and avidin, biotin and streptavidin, biotin and neutravidin (a deglycosylated version of avidin), lectin and carbohydrates. Preferred binding pairs are biotin and streptavidin, biotin and avidin, biotin and neutravidin, fluorescein and anti-fluorescein, digoxigenin/anti-digoxigenin, DNP (dinitrophenol)/anti-DNP.

30 **[0015]** A "branched polymer," as used herein, refers to a non-linear polymer having a 2- or 3-dimensional structure, which can be either a naturally occurring branched polymer, or a synthetically crosslinked polymer.

[0016] "Chemiluminescence," as used herein, refers to the emission of energy with limited emission of luminescence, as the result of a chemical reaction. For example, when luminol reacts with hydrogen peroxide in the presence of a suitable catalyst, it produces 3-aminophthalate in an excited state, which emits light when it decays to a lower energy level.

35 **[0017]** A "dendrimer," as used herein, refers to repetitively organic, branched molecules. A dendrimer is typically symmetric around the core, and often adopts a spherical three-dimensional morphology.

[0018] "Electrochemiluminescence," (ECL), as used herein, refers to luminescence produced during electrochemical reactions in solutions. In ECL, electrochemically generated intermediates undergo a highly exergonic reaction to produce an electronically excited state and then emits light. ECL excitation is caused by energetic electron transfer (redox) reactions of electrogenerated species. ECL is usually observed during application of potential (several volts) to electrodes of electrochemical cell that contains solution of luminescent species

40 **[0019]** "Immobilized," as used herein, refers to reagents being fixed to a solid surface. When a reagent is immobilized to a solid surface, it is either be non-covalently bound or covalently bound to the surface.

45 **[0020]** A "monolithic substrate," as used herein, refers to a single piece of a solid material. A "probe," as used herein, refers to a substrate coated with a thin-film layer of analyte-binding molecules at the sensing side. A probe has a distal end and a proximal end. The proximal end (also refers to probe tip in the application) has a sensing surface coated with a thin layer of analyte-binding molecules.

High Sensitivity Luminescent Immunoassay

50 **[0021]** The present invention is directed to a high sensitivity immunoassay method. The inventors have discovered that the unique combination of (i) using a probe having a small sensing surface area for binding analyte molecules, (ii) using a high molecular weight branched polymer conjugated with multiple binding molecules and multiple luminescent labels, and (iii) cycling the probe having immunocomplex formed back to the reagent vessel and amplification vessel 1-10 times and repeating the reaction with the reagent and the amplification polymer, improves the sensitivity of detection level. For each cycling, the luminescent signal is increased significantly over the noise.

55 **[0022]** The present method offers high sensitivity and precision without increasing the overall complexity of the assay reagents, consumable and instrumentation. The method entails the transfer of a probe back and forth between two

reagents one of which is an amplification polymer labeled with multiple binding molecules and multiple luminescent labels. The polymer has a molecular weight of ≥ 1 million Dalton. Crosslinking of the polymer is desirable to control the molecular size distribution and non-specific binding. The polymer should carry at the minimum 5 binding molecules per polymer, preferably more than 10. Luminescent labels should be small with a molecular weight of $< 2K$ Dalton. The inventors have discovered that simply cycling the reactions without using the polymer as described above in the amplification does not improve the sensitivity.

[0023] The present method detects an analyte in a liquid sample. The method comprises the steps of: (a) obtaining a probe having a first antibody immobilized on the tip of the probe, wherein the diameter of the tip surface is ≤ 5 mm; (b) dipping the probe tip into a sample vessel containing a sample solution having an analyte to bind the analyte to the first antibody on the probe tip; (c) dipping the probe tip into a reagent vessel containing a reagent solution comprising a reagent of a second antibody conjugated with a first member of a binding pair to bind the reagent to the analyte; (d) dipping the probe tip into a first wash vessel containing a wash solution to wash the probe tip; (e) dipping the probe tip into an amplification vessel containing an amplification solution comprising a polymer conjugated with at least 5 molecules of second member of the binding pair and at least 25 luminescent labels, to form an immunocomplex of the analyte, the first antibody, the second antibody, and the first and the second members of the binding pair on the probe tip, wherein the polymer is branched, and has a molecular weight of at least 1 million daltons, and the luminescent labels have a molecular weight of less than 2,000 Daltons; (f) dipping the probe tip into a second wash vessel containing a wash solution to wash the probe tip; (g) repeating steps (c) to (f) 1-10 times, and (h) detecting the immunocomplex formed by measuring the luminescent signal on the probe tip; wherein the first antibody and the second antibody are antibodies against the analyte.

[0024] In step (a), the probe can be any shape such as rod, cylindrical, round, square, triangle, etc., with an aspect ratio of length to width of at least 5 to 1, preferably 10 to 1. A rod-shape is preferred. Because the probe is dipped in a sample solution and one or more assay solutions during an immunoassay, it is desirable to have a long probe with an aspect ratio of at least 5 to 1 to enable the probe tip's immersion into the solutions. For fluorescent assay, the probe can be a monolithic substrate.

[0025] The probe has a small tip for binding analytes. The tip has a smaller surface area with a diameter ≤ 5 mm, preferably ≤ 2 mm or ≤ 1 mm, e.g., 0.5-2 mm. The small surface of the probe tip provides several advantages. First, a small surface has less non-specific binding and thus produces a lower background signal. Second, the reagent or sample carry over on the probe tip is extremely small due to the small surface area of the tip. This feature makes the probe tip easy to wash, and causes negligible contamination in the wash solution since the wash solution has a larger volume. Further, small surface area of the probe tip has a small binding capacity. Consequently, when the probe tip is immersed in a reagent solution, the binding of the reagent does not consume a significant amount of the reagent. The reagent concentration is effectively unchanged. Negligible contamination of the wash solution and small consumption of the reagents enable the reagent solution, the amplification solution, and the wash solution to be re-used many times, for example, 1-10 times.

[0026] The sensing surface of the probe is coated with first antibody which binds to the analyte in a sample. Methods to immobilize reagents to the solid phase (the sensing surface of the probe tip) are common in immunochemistry and involve formation of covalent, hydrophobic or electrostatic bonds between the solid phase and reagent. The first antibody can be directly immobilized on the sensing surface. Alternatively, the first antibody can be indirectly immobilized on the sensing surface through a binding pair. For example, anti-fluorescein can be first immobilized either by adsorption to the solid surface or by covalently binding to aminopropylsilane coated on the solid surface. Then the first antibody that is labeled with fluorescein can be bound to the solid surface through the binding of fluorescein and anti-fluorescein (binding pair).

[0027] In step (b), the probe tip can be dipped into a sample vessel for 20 seconds to 60 minutes, preferably 20 seconds to 10 minutes, to bind the analyte to the first antibody on the probe tip.

[0028] After step (b), the probe can be optionally washed 1-5 times, preferably 1-3 times in a wash vessel containing a wash solution. This extra washing step may not be required because the amount of the carried-over solution is minimal due to a small binding surface area. The wash solution typically contains buffer and a surfactant such as Tween 20.

[0029] In step (c), the probe tip can be dipped into a reagent vessel for 20 seconds to 10 minutes, preferably 20 seconds to 2 minutes to bind the reagent to the analyte on the probe tip. The reagent solution comprises a reagent of a second antibody conjugated with a first member of a binding pair.

[0030] The binding pair is typically a hapten and its antibody, a ligand and its receptor, complementary strands of nucleic acids, or lectin and carbohydrates. For example, the binding pair is biotin and streptavidin, biotin and avidin, biotin and neutravidin, fluorescein and anti-fluorescein, digoxigenin and anti-digoxigenin, and DNP (dinitrophenol) and anti-DNP. Preferably, the first member of the binding pair is biotin and the second member of the binding pair is streptavidin.

[0031] In Step (d), the probe can be washed 1-5 times, preferably 1-3 times in a wash vessel containing a wash solution. The wash solution typically contains buffer and a surfactant such as Tween 20.

[0032] In step (e), the probe can be dipped into an amplification vessel containing an amplification solution for 20

seconds to 5 minutes, preferably 20 seconds to 2 minutes, to form an immunocomplex of the analyte, the first antibody, the second antibody, and the first and the second members of the binding pair on the probe tip. The amplification solution comprises a polymer conjugated with at least 5 molecules of second member of the binding pair and at least 25 luminescent labels. The polymer is branched, and has a molecular weight of at least 1 million Daltons. In unclaimed embodiments, the polymer has a molecular weight of at least 500,000 Daltons. The polymer can be a polysaccharide (e.g. ficoll or dextran), a polynucleotide, a dendrimer, a polyols, or polyethylene glycol. The polymer is preferably branched to have a 2- or 3- dimensional structure. The polymer preferably comprises 5-50 and 25-100 luminescent molecules. In unclaimed embodiments, the polymer comprises 5-100 binding molecules and 25-500 luminescent molecules.

[0033] The luminescent label useful for this invention has a molecular weight of < 2,000, such as 500-2000 or 100-2000 Daltons. In unclaimed embodiments, the luminescent label has a molecular weight of <5,000 Daltons. In one embodiment, the luminescent label is a fluorescent dye selected from the group consisting of: cyanine, coumarin, xanthene and a derivative thereof. For example, the fluorescent dye is Cy5 (molecule weight MW 792), Alexa Fluor 647, DyLight 350 (MW 874), DyLight 405 (MW793), DyLight 488 (MW 71011), DyLight 550 (MW 982), DyLight 594 (MW 1078), DyLight 633 (MW 1066), DyLight 650 (MW 1008), DyLight 680 (MW 950), DyLight 755 (MW 1092), DyLight 800 (MW 1050), an Oyster fluorescent dye, IRDye, or organic compounds comprising multiple rings chelated with a rare earth metal such as a lanthanide (Eu, Th, Sm, or Dy).

[0034] In another embodiment, the luminescent label is a chemiluminescent marker selected from the group consisting of: Ruthenium(II)tris-bipyridine (MW 1057), luminol (MW 177), acridinium ester (9[[4-[3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropyl]phenoxy]carbonyl]-10-methyl-acridinium trifluoromethane sulfonate, MW 632), hemin (MW 652).

[0035] When the binding molecule is a polypeptide or protein, the luminescent label can covalently bind to it through a variety of moieties, including disulfide, hydroxyphenyl, amino, carboxyl, indole, or other functional groups, using conventional conjugation chemistry as described in the scientific and patent literature.

[0036] Covalent binding of a binding molecule to a polynucleotide can be effected through a variety of moieties, including aldehyde, ketone, isothiocyanate, imidate, inosine, acyl, and alkyl, using conventional conjugation chemistry, while derivatization with biotin is taught in many references. (Leary et al. (1983) Proc. Natl. Acad. Sci. USA 80:4045-4049; WO86/02929; EP063 879; Langer et al. (1981) Proc. Natl. Acad. Sci. USA 78:6633-6637; and EP2009 996).

[0037] In each step (b), (c), and (e), the reaction can be accelerated by agitating or mixing the solution in the vessel. For example, a lateral flow (orbital flow) of the solution across the probe tip can be induced, which accelerates the capture of target molecules by its binding partner immobilized to solid phase. For example, the reaction vessel can be mounted on an orbital shaker and the orbital shaker is rotated at a speed at least 50 rpm, preferably at least 200 rpm, more preferably at least 500 rpm, such as 500-1,000 rpm. Optionally, the probe tip can be moved up and down and perpendicular to the plane of the orbital flow, at a speed of 0.01 to 10 mm/second, in order to induce additional mixing of the solution above and below the probe tip.

[0038] In Step (f), the probe can be washed 1-5 times, preferably 1-3 times in a wash vessel containing a wash solution. The wash solution typically contains buffer and a surfactant such as Tween 20.

[0039] Step (g) is cycling amplification by repeating steps (c)-(f) 1-10 times, preferably 1-5 times or 2-3 times. Each cycle consists of placing the probe back to the same reagent vessel, the same first wash vessel, the same amplification vessel, and the same second wash vessel.

[0040] In Step (h), the immunocomplex is detected by reading the luminescent signal on the on the probe is detected. For a fluorescent label, the probe can be placed in a clear-bottom well and read by a detector, such as those described in US 2011/0312105 (FIG. 1),

[0041] For a chemiluminescent label, the probe can be placed in a clear-bottom well containing a measurement solution having a co-reactant. For example, if the chemiluminescent label is Ruthenium(II)tris-bipyridine, the co-reactant is tripropylamine. If the chemiluminescent label is luminol, the co-reactants are hydrogen peroxide and a hydroxide salt in water. The light emitted is measured by a photomultiplier tube (PMT).

[0042] For electrochemiluminescence (ECL), the mechanism and the principal components of the ECL analyzer is described by Blackburn et al (Clin. Chem. 37: 1534-1539 (1991)). After the probe is placed in a clear-bottom well containing a measurement solution having a co-reactant, a voltage is applied to the working electrode and counter electrode, and the emitted light is measured by PMT.

[0043] In an unclaimed embodiment, the antibody-coated probe serves as the working electrode of ECL analyzer (FIG. 2). This offers the advantage of efficient luminescence generation since the Ru(II)/tripropylamine red-ox reaction needs to occur at the electrode surface or very close proximity.

[0044] FIG. 3 illustrates one embodiment of an immunoassay format for detecting an antigen analyte. FIG. 4 illustrates the probe transfer in cyclic amplification.

[0045] There are several key features in the luminescent polymer that enable the cyclic amplification. The polymer itself should have low non-specific binding, should be greater than 400 or 500 kD in molecular weight to serve as an effective carrier of multiple binding molecules such as streptavidins. The ability to carry multiple binding molecules is important to enhance biotin binding capacity and to form alternating layers such as biotinylated antibody and streptavidin

polymer. The polymer should be branched or crosslinked and have a two or three dimensional structure to further facilitate multiple layer formation. The size of the label is also a critical parameter. A high molecular weight label when conjugated to streptavidin is likely to alter its biotin binding capacity and present steric hindrance during multiple layer formation in cyclic amplification. The labels should be small, having molecule weights ≤ 5000 Daltons; preferably ≤ 2000 Daltons.

5 [0046] When the polymer conjugate binds to the first layer of biotin-antibody in the immune complex, it has sufficient residual biotin binding capacity to form another layer of biotin-antibody. The size of the polymer and its branched structure create an extended three dimensional complex on the probe surface that minimizes steric hinderance in the binding between the biotin-antibody and the polymer conjugate to form additional layers. The molecular weight of the polymer is large enough so that the labeled-streptavidin molecules are spaced apart. In a fluorescence assay, the space reduces energy transfer mediated fluorescent quenching. In an electrochemiluminescence assay, there is a similar advantage due to the spacing and structure of the polymer. The Ru(bpy) label bound in an immune complex on a solid phase reacts with tripropylamine (TPA) which is fluid phase. The Ru(bpy)/TPA decays emitting a photon regenerating the Ru(bpy) to react with another molecule of TPA. Eventually the TPA becomes depleted. If the Ru(bpy) label is densely packed on the surface, the TPA will become more quickly locally depleted. The crosslinked polymer yields more efficient chemiluminescence due to its spacing between the chemiluminescent label.

10 [0047] Negligible cyclic amplification with monomeric streptavidin labeled with Cy5 was observed. One would expect monomeric streptavidin with 4 binding sites and antibody labeled with 4-5 biotins could form alternating layers on the probe surface. However, probe surface where one member of the binding pair is already bound could limit its degree of rotation and sterically hinder a consequently layer formation. A second possibility for the Cy5-streptavidin's negative result is that there is layer formation but the Cy5 fluorescence is quenched. Cy5, as common with many fluorescent dyes, can have its fluorescence quenched, typically by a excitation energy transfer mechanism. The efficiency of energy transfer quenching is dependent on the distance between the donor and acceptor dyes. The formation of alternating layers can create densely packed Cy5-streptavidin where the Cy5 molecules are in close proximity and thus enabling quenching of fluorescence.

15 [0048] Another remarkable aspect of cyclic amplification is that the probe is transferred back and forth between the same reagent vessel, wash vessel, and amplification vessel, without having to use new vessels containing new solutions. The small surface area of the probe minimizes depletion of the reagent and the amplification polymer during the binding steps. This feature greatly simplifies the reagents required for the assay and overall consumable system designs. Each binding step in the cyclic amplification is only a short period of 30 seconds to 2 minutes, for example, one minute. Consequently, cyclic amplification does not caused pronged assay times. High sensitivity assays with times from 10 -15 minutes are feasible.

High Molecular Weight Branched Polymer Containing Multiple Binding Molecules and Chemiluminescent Labels.

20 [0049] The present disclosure also describes a composition comprising (a) a branched polymer, having a molecular weight of at least 500,000 or 1 million Daltons, (b) at least 5 binding molecules, and (c) at least 25 chemiluminescent molecules, wherein the binding molecules and the chemiluminescent molecules are attached to the cross-linked Ficoll. The composition preferably comprises 5-50 or 5-100 binding molecules and 25-100 or 25-500 chemiluminescent molecules. The polymer can be a polysaccharide (e.g. ficoll or dextran), a polynucleotide, a dendrimer, a polyols, or polyethylene glycol. Polysaccharides in general exhibit negligible non specific binding to many of the solid phase materials commonly employed in immunoassays. Ficoll is commercially available in 70K and 400K Dalton molecular weights. Crosslinked Ficoll is a preferably polymer.

25 [0050] The chemiluminescent label useful for this composition has a molecular weight of $< 5,000$, preferably $< 2,000$, such as 500-2000 or 100-2000 Daltons. Preferred chemiluminescent molecules include, but are not limited to, ruthenium(II)tris-bipyridine, luminol, acridinium ester, and hemin.

30 [0051] In one example, the chemiluminescent molecules are attached directly to the polymer. In another example, the chemiluminescent molecules are attached indirectly to polymer through a binding pair.

Electrochemiluminescent Detection Device

35 [0052] The present disclosure also describes an electrochemiluminescent detection system for measuring a chemiluminescent signal on a probe tip.

40 [0053] An electrochemiluminescent system comprising: (a) a probe having an aspect ratio of length to width at least 5 to 1, the probe having a first end and a second end, the second end having a sensing surface coated with an antibody and bound with an immunocomplex having a chemiluminescent label, wherein the probe is made of a conductive material and serves as a working electrode to produce an electrochemical reaction; (b) a counter electrode; (c) a collecting lens pointed toward the sensing surface; and (d) an optical detector for detecting the light emitted from the chemiluminescent label; wherein the collecting lens collects and directs the emitted light to the optical detector.

[0054] The probe can be constructed from any conductive material such as metals, metal oxides and carbon, e.g., silver, gold, platinum, copper, TiO₂, graphite, and any combination thereof. The probe can be any shape such as rod, cylindrical, round, square, triangle, etc., with an aspect ratio of length to width of at least 5 to 1, preferably 10 to 1. Because the probe is dipped in a sample solution and one or more assay solutions during an immunoassay, it is desirable to have a long probe with an aspect ratio of at least 5 to 1 to enable the probe tip's immersion into the solutions. The sensing surface of the probe is coated with analyte-binding molecules such as antibodies and bound with chemiluminescent labels.

[0055] In a preferred example, the probe has a small tip for binding molecules. The tip has a smaller surface area with a diameter ≤ 5 mm, preferably ≤ 2 mm or ≤ 1 mm, e.g., 0.5-2 mm. The small surface of the probe tip provides several advantages. The present invention uses a probe that has a small tip for binding analytes. The tip has a smaller surface area with a diameter ≤ 5 mm, preferably ≤ 2 mm or ≤ 1 mm, e.g., 0.5-2 mm. The small surface of the probe tip provides several advantages such as low non-specific binding, small carry-over of the reagents, easy to wash, and small consumption of the reagents.

[0056] The photon of the emitted light is detected by photomultiplier tubes (PMT), silicon photodiode, or gold coated fiber-optic sensors.

[0057] FIG. 2 shows one example of the electrochemiluminescent system. The lower end of the rod is used as a sensing surface. Chemiluminescent labels are bonded to the sensing surface. To detect the luminescence, the rod's sensing end is immersed into a vessel with a clear bottom that contains a measurement solution containing a co-reactant. The clear bottom's material may be selected from plastic, glass or quartz. A ramp voltage is applied to the working electrode and the counter electrode, the emitted light is corrected by collecting lens and directed to PMT for measurement.

[0058] The unique aspect of the system is that the probe serves as the working electrode, which offers the advantage of efficient luminescence generation since the Ru(II)/tripropylamine red-ox reaction needs to occur at the electrode surface or very close proximity. The optical device as configured is capable of applying a multitude of voltage waveforms at the working surface electrode with luminescence generally occurring around 1 volt.

[0059] The invention is illustrated further by the following examples that are not to be construed as limiting the invention in scope to the specific procedures described in them.

EXAMPLES

Example 1: Preparation of Probe Having Immobilized First Antibody

[0060] Quartz probes, 1 mm diameter and 2 cm in length, were coated with aminopropylsilane using a chemical vapor deposition process (Yield Engineering Systems, 1224P) following manufacturer's protocol. The probe tip was then immersed in a solution of murine monoclonal anti-fluorescein (Biospacific), 10 $\mu\text{g/ml}$ in PBS (phosphate-buffered saline) at pH 7.4. After allowing the antibody to adsorb to the probe for 20 minutes, the probe tip was washed in PBS.

[0061] Capture antibodies for troponin I (TnI) and brain natriuretic peptide (BNP), obtained from HyTest, were labeled with fluorescein by standard methods. Typically, there were about 4 fluorescein substitutions per antibody. Anti-fluorescein coated probes were immersed in fluorescein labeled capture antibody solution, 5 $\mu\text{g/ml}$, for 5 minutes followed by washing in PBS.

Example 2. Preparation of Crosslinked Ficoll 400-SPDP

[0062] Crosslinked Ficoll 400-SPDP (succinimidyl 6-[3-[2-pyridyldithio]-propionamido]hexanoate, Invitrogen) was prepared according to Example 1 of US 2001/0312105. FIG. 5 shows a flow chart of its preparation.

Example 3. Preparation of Cy5- Streptavidin

[0063] 32 μL of Cy 5-NHS (GE Healthcare) at 5 mg/ml in DMF reacted with 1 ml of streptavidin (Scripps Labs) at 2.4 mg/ml in 0.1 M sodium carbonate buffer pH 9.5 for 40 minutes at 30°C. Applying the mixture to a PD 10 column (Pharmacia) removed unconjugated Cy 5. Spectral analysis indicated 2.8 Cy 5 linked per streptavidin molecule.

Example 4. Preparation of Cy5- Streptavidin-Crosslinked Ficoll

[0064] 5.8 μL of SMCC (succinimidyl 4-[N-maleimidomethyl]cyclohexan-1-carboxylate) Pierce Chemical) at 10 mg/ml in DMF reacted with 2 mg Cy5-streptavidin (Example 2) in 1 ml PBS pH 7.4 for 1 hour at room temperature. Applying the mixture to a PD 10 column removed unbound SMCC.

[0065] The thiols on crosslinked Ficoll 400-SPDP were deprotected by adding 30 μL DTT at 38 mg/ml to 1 mg crosslinked Ficoll 400-SPDP in 1 ml PBS and reacting for 1 hour at room temperature followed by a PD 10 column to

purify the crosslinked Ficoll.

[0066] The Cy5-streptavidin-SMCC was mixed with crosslinked Ficoll 400-SH and reacted overnight at room temperature. 10 µL NEM (Aldrich) at 12.5 mg/ml was then added and reacted for ½ hour at room temperature. The conjugate was then purified on a Sepharose 4B CL column. It was estimated that the conjugate carried about 20 to 30 streptavidins per ficoll (2 million Daltons), and 2-3 Cy5s per streptavidin.

Example 5: Cy5- Streptavidin vs. Cy5-Streptavidin-Crosslinked Ficoll at 1st Read (No Cycling)

[0067] A BNP assay was used to compare fluorescence signals of Cy5- Streptavidin and Cy5-Streptavidin-Cx Ficoll. The assay used a sandwich pair of BNP monoclonal antibodies, (Hytest). One was labeled with fluorescein and the second with biotin. Both labeling were done by standard methods with 4-5 haptens substituted per antibody. The fluorescein-antibody was bound to the probe as described in Example 1. For the assay, BNP calibrators (Hytest) were spiked into normal, pooled human plasma and then diluted 3 fold in PBS with 5 mg/ml BSA and 0.05% Tween 20 (assay buffer). The probe tip was immersed in the BNP samples and incubated for 5 minutes at room temperature with the sample wells subjected to orbital movement (1 mm diameter stroke) at 750 rpm. The probe was held stationary. The probe was washed 3 times for 10 seconds in PBS, 0.05% Tween 20. After the wash sequence, the probe was immersed in a solution containing biotinylated anti-BNP at 10 µg/ml in assay buffer, followed with a 2 min incubation at 500 rpm, then a 3x wash sequence. Probes were then transferred to solutions containing either Cy5- Streptavidin (Example 2) or Cy5-streptavidin-Cx Ficoll (Example 3). The streptavidin in both cases was labeled with about 2-3 Cy5s and at a comparable concentration of 10 µg/ml. After one minute incubation at 500 rpm, the probes were taken through a wash sequence. Fluorescence at the distal tip of the probe was then measured in a optical configuration illustrated in FIG. 1. The assay configuration with the Cy5-streptavidin-Cx Ficoll is diagramed in FIG. 4. The results are shown in Table 1. Measurements after the first binding are termed the first read (no cycling).

Table 1. First Read: Cy5-Streptavidin vs. Cy5-Streptavidin- Crosslinked Ficoll

	Cy5-SA	Cy5-SA-Cx Ficoll
	Voltage	Voltage
BNP, ng/ml		
18	0.32	6.27
9	0.25	5.35
3	0.15	3.03
1	0.15	1.71
0.3	0.11	0.8
0.1	0.11	0.32
0	0.12	0.16

Data are mean of duplicate determinations

[0068] The results in Table 1 show that Cy5-streptavidin can only detect BNP above background about 9 to 18 ng/ml, while the ficoll conjugate can readily detect as low as 0.1 ng/ml. The results demonstrate that the high molecular weight ficoll polymer can serve to increase sensitivity.

Example 6: Cyclic Amplification

[0069] At the end of the 1st read, the probes of Example 5 were carried out further amplification cycles. A cycle consists of placing probes back in the same biotin-antibody solution for 1 min at 500 rpm, followed a wash sequence, then back in the streptavidin solution for one minute at 500 rpm followed by a wash sequence. The cycles are intended to build up alternating layers of biotin-antibody and streptavidin. FIG. 5 depicts the transfer of the probe from well to well during the cyclic amplification process. At the end of each amplification cycle, fluorescence at the probe tip is measured.

[0070] Table 2 shows a continuation of the BNP assay from Table 1, where the probes underwent two amplification cycles, Cycle 1 and Cycle 2.

EP 2 699 906 B1

Table 2. Cycling Amplifications: Cy5-Streptavidin vs. Cy5-Streptavidin-Crosslinked Ficoll

	Cy5-SA			Cy5-SA-Cx Ficoll		
	1st Read	Cycle 1	Cycle 2	1st Read	Cycle 1	Cycle 2
BNP ng/ml						
18	0.32	0.38	0.41	6.27	8.36	10.92
9	0.25	0.27	0.28	5.35	7.78	10.49
3	0.15	0.21	0.22	3.03	4.77	7.01
1	0.5	0.15	0.16	1.71	2.77	4.41
0.3	0.11	0.11	0.11	0.8	1.37	2.19
0.1	0.11	0.11	0.12	0.32	0.53	0.82
0	0.12	0.12	0.13	0.16	0.25	0.36

Data are mean of duplicate determinations

[0071] The results of Table 2 indicate that the Cy5-streptavidin does not have significant increase in signal through 2 cyclic amplification cycles. On the contrary, the Cy5-streptavidin-crosslinked ficoll conjugate shows about a doubling of fluorescence signal after two cycles beyond the initial binding (1st Read). These results indicate that achieving cyclic amplification with alternating layers of biotin-antibody and Cy5-streptavidin is not a matter solely depending transferring the probe back and forth between the two reagents. Cyclic amplification can only be achieved with the Cy5-streptavidin-crosslinked ficoll conjugate.

Example 7: BNP Assay with Cyclic Amplification

[0072] Table 3 contains results of a BNP assay, performed with the same protocol as in Example 5, with more cycling amplification steps.

Table 3. BNP Assay with Multiple Cycling Amplification Steps

	1st Read	Cycle 1	Cycle 2	Cycle 3	Cycle 4
BNP,pg/ml					
580	1.13	3.11	6.37	11.49	PMT sat.
58	0.18	0.42	0.82	1.51	2.57
14	0.13	0.29	0.58	1.06	1.81
0	0.15	0.23	0.42	0.75	1.27

Data are mean of duplicate determinations

[0073] The results of Table 3 indicate that the cycling amplification boosts sensitivity in immunoassays. In this example, the signal of 14 pg/ml BNP sample is comparable to that of the negative sample at the first read. After the 2nd cycle amplification, the 14 pg/ml is readily resolved. The assay performed 4 amplification cycles and the fluorescence signals steadily increased after each cycle.

[0074] As many as 9 amplification cycles have been performed in other experiments and the fluorescence signals still steadily increased after each cycle.

Example 8: Tnl Assay with Cyclic Amplification

[0075] Table 4 presents data from a troponin I (Tnl) assay using the cyclic amplification method. A sandwich pair of monoclonal antibodies (Hytest) was used, one of which was labeled with fluorescein and the second with biotin. The hapten labeling were by standard methods. Probe coating with the fluorescein-anti-Tnl was as described in Example 1. The anti-Tnl coated probe was immersed in Tnl samples diluted 3 fold in assay buffer and incubated at room temperature for 20 minutes with samples wells subjected to orbital flow of 750 rpm. After a wash sequence, the probes were immersed

EP 2 699 906 B1

in a solution of B-anti-Tnl at 10 μg/ml for 2 minutes at 500 rpm, followed by incubation in the Cy5-SA-ficoll reagent for 1 minute with 500 rpm flow. Two subsequent amplification cycles were performed by cycling the probe back into the B-anti-Tnl solution (1 min incubation) thru wash sequence to Cy5-SA-Ficoll (1minute incubation) followed by a wash sequence. All steps were performed at room temperature with 500 rpm flow. At the completion of each amplification cycle, fluorescence of the probe tip was measured and the results are shown in Table 4.

Table 4. Troponin I Assay with Cycling Amplification Steps

	1st Read	Cycle 1	Cycle 2
Tnl, pg/ml			
1000	2.34	7.06	13.41
100	0.54	1.43	3.17
10	0.31	0.66	1.43
0	0.31	0.53	1.04
Note: Data mean of duplicate determinations			

[0076] Data depicted in Table 4 shows that cyclic amplification method boosts sensitivity. The 10 pg/ml Tnl sample, which at the first read is undetected, has its fluorescence greater than the negative sample after 2 cycles of amplification.

Example 9: Assay Precision with Cyclic Amplification

[0077] One would expect that with the formation of multiple layers of high molecular weight complexes that imprecision would increase with more amplification steps. However, Table 5 illustrates another unexpected aspect of the cyclic amplification method.

[0078] A precision study was performed using clinically relevant BNP levels following the protocol described in Example 5. The % CV (coefficient of variation) for BNP concentration units (pg/ml) are shown in Table 5. The results show that the cycling amplification method has high precision with a C.V. of <10 %.

Table 5. BNP Assay Precision

BNP	100 pg/ml	500 pg/ml	1500 pg/ml
1st Read	17.3% CV	2.2% CV	4.4% CV
Cycle 1	8.1% CV	2.5% CV	4.6% CV
Cycle 2	7.4% CV	2.8% CV	5.5% CV
	n=8	n=8	n=8

Example 10: Reduction in Minimum Detection Limit

[0079] Table 6 shows results of BNP assays performed with three cycling amplification steps using protocols described in Examples 4 & 5. Results of a BNP calibration curve and the mean, standard deviation, and two standard deviations of 16 replicates of a negative sample are in Table 6. The high end of the BNP appears to start saturating the probe at around 3 to 6 ng/ml and the assay has sensitivity down to the low pg/ml range. 2 standard deviations is a common means of determining the minimum detection limit of an immunoassay. Data in Table 6 show that the minimum detection limit progressively decreases from 6.4 pg/ml at first read to 1 pg/ml after 3 cycling amplification. At first read, the S.D. of the negative sample is 0.0078 V, where the major source of variation is the particular instrument employed in the assay. Instrument Variation is about ± 0.007V. With cyclic amplification, the sensitivity is improved by increasing the immuno-specific signal while the instrument measurement noise remains constant.

Table 6. Minimum Detection Limit Improvement with Cyclic Amplification.

				PMT Voltage				
BNP (pg/ml):	6000	3000	1000	333	111	37	12	0
1st Read	9.48	7.87	4.3	2.32	0.83	0.29	0.07	0.04
Cycle 1	11.62	10.14	6.7	4.53	1.8	0.66	0.16	0.06
Cycle 2	Sat.	12.37	8.73	6.94	3.2	1.22	0.29	0.09
Cycle 3	Sat.	Sat.	10.6	9.14	4.91	2.01	0.45	0.13
		Neg.	S.D.* (n=16)	2x S.D.	Detection Limit			
					(pg/ml)			
1st Read		0.04	0.0079	0.016	6.4			
Cycle 1		0.06	0.012	0.024	3.7			
Cycle 2		0.09	0.015	0.03	2.4			
Cycle 3		0.13	0.016	0.032	1.1			

Example 11: Preparation of Streptavidin-Crosslinked Ficoll with Chemiluminescent Labels

[0080] 0.176 μg of Ruthenium(II)tris-bipyridine-NHS (MesoScale Discovery, R91BN-2) in 35 μl dimethylformamide is mixed with 1 mg streptavidin in PBS pH 7.4 and allowed to react for one hour at room temperature. Typically about 2 to 4 Ru labels are linked per streptavidin molecule. The resulting Ru-streptavidin conjugate is purified on a PD-10 column (Pharmacia). 2.9 μL of SMCC (Pierce Chemical) at 10 mg/ml in DMF reacted with 1 mg of Ru-streptavidin in 1 ml PBS pH 7.4 for 1 hour at room temperature. The mixture is applied to a PD 10 column to remove unbound SMCC.

[0081] The thiols on crosslinked Ficoll 400-SPDP are deprotected by adding 30 μL DTT at 38 mg/ml to 1 mg crosslinked Ficoll 400-SPDP in 1 ml PBS and reacting for 1 hour at room temperature followed by a PD 10 column to purify the crosslinked Ficoll.

[0082] The Ru-streptavidin-SMCC is mixed with crosslinked Ficoll 400-SH and reacted overnight at room temperature. 10 μL NEM (Aldrich) at 12.5 mg/ml is then added and reacted for $\frac{1}{2}$ hour at room temperature. The conjugate is then purified on a Sepharose 4B CL column. The resulting conjugate has about 20 streptavidins per crosslinked ficoll and 2-4 Ru per streptavidin.

Example 12: Cyclic Amplification with Chemiluminescent Labels

[0083] 1 mm diameter anti-BNP coated probe, prepared as described in Example 1, is immersed in the BNP samples and incubated for 5 minutes at room temperature with the sample wells subjected to orbital movement (1 mm diameter stroke) at 750 rpm. The probe was held stationary. The probe is washed 3 times for 10 seconds in PBS, 0.05% Tween 20. After the wash sequence, the probe is immersed in a solution containing biotinylated anti- BNP at 10 $\mu\text{g}/\text{ml}$ in assay buffer, followed with a 2 minute incubation at 500 rpm, then a 3x wash sequence. The probe is then transferred to solutions containing Ru-streptavidin-Cx Ficoll at a concentration of 10 $\mu\text{g}/\text{ml}$. After 1 minute incubation at 500 rpm, the probes are taken through a wash sequence, then undergo 2 amplification cycles. A cycle consists of placing probes back in the same biotin-antibody solution for 1 min at 500 rpm, followed a wash sequence, then back in the streptavidin solution for one minute at 500 rpm, and followed by a wash sequence. At the completion of the last wash step, the probe is immersed in a clear bottom microwell containing the measurement solution with the co-reactant, tripropylamine (MesoScale Discovery, Read Buffer S, R92SC-3), and read by the optical device of FIG. 2.

[0084] The invention, and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

Claims

1. A method of detecting an analyte in a liquid sample, comprising the steps of:

- 5 (a) obtaining a probe having a first antibody immobilized on the tip of the probe, wherein the diameter of the tip surface is ≤ 5 mm;
 (b) dipping the probe tip into a sample vessel containing a sample solution having an analyte to bind the analyte to the first antibody on the probe tip;
 10 (c) dipping the probe tip into a reagent vessel containing a reagent solution comprising a reagent of a second antibody conjugated with a first member of a binding pair to bind the reagent to the analyte;
 (d) dipping the probe tip into a first wash vessel containing a first wash solution to wash the probe tip;
 (e) dipping the probe tip into an amplification vessel containing an amplification solution comprising a polymer conjugated with at least 5 molecules of second member of the binding pair and at least 25 luminescent labels, to form an immunocomplex of the analyte, the first antibody, the second antibody, and the first and the second
 15 members of the binding pair on the probe tip, wherein the polymer is branched, and has a molecular weight of at least 1 million daltons, and the luminescent labels have a molecular weight of less than 2,000 Daltons;
 (f) dipping the probe tip into a second wash vessel containing a second wash solution to wash the probe tip;
 (g) repeating steps (c) to (f) 1-10 times, and
 (h) detecting the immunocomplex formed by measuring the luminescent signal on the probe tip; wherein the
 20 first antibody and the second antibody are antibodies against the analyte.

2. The method according to Claim 1, wherein the tip surface is \leq about 2 mm.

3. The method according to Claim 1, wherein the binding pair is a hapten and its antibody, a ligand and its receptor, complementary strands of nucleic acids, or lectin and carbohydrates.

4. The method according to Claim 3, wherein the binding pair is biotin and streptavidin, biotin and avidin, biotin and neutravidin, fluorescein and anti-fluorescein, digioxygenin/anti-digioxygenin, or DNP-anti-DNP,

5. The method according to Claim 4, wherein the first member of the binding pair is biotin and the second member of the binding pair is streptavidin.

6. The method according to Claim 1, wherein the polymer is a polysaccharide, a polynucleotide, a dendrimer, a polyol, or polyethylene glycol.

7. The method according to Claim 1, wherein the polymer is crosslinked ficoll.

8. The method according to Claim 1, wherein the luminescent label is a fluorescent dye selected from the group consisting of: cyanine, coumarin, xanthene and a derivative thereof.

9. The method according to Claim 1, wherein the luminescent label is a chemiluminescent molecule selected from the group consisting of: ruthenium(II)tris-bipyridine, luminol, acridinium ester, and hemin.

10. The method according to Claim 1, wherein the polymer is conjugated with 5-50 binding molecules and 25-100 luminescent molecules.

11. The method according to Claim 1, wherein the polymer is crosslinked ficoll and is conjugated with 20-30 streptavidin and 40-90 Cy 5.

12. The method according to Claim 1, wherein steps (c) to (f) are repeated:

- (i) 1-5 times; or
 (ii) 2-3 times.

Patentansprüche

1. Verfahren zum Nachweisen eines Analyten in einer flüssigen Probe, die folgenden Schritte umfassend:

EP 2 699 906 B1

- (a) Erhalten einer Sonde mit einem ersten auf der Sondenspitze immobilisierten Antikörper, wobei der Durchmesser der Spitzenerfläche ≤ 5 mm ist;
- (b) Eintauchen der Sondenspitze in einen Probenbehälter, der eine Probelösung enthält, die einen Analyten aufweist, um den Analyten an den ersten Antikörper der Sondenspitze zu binden;
- 5 (c) Eintauchen der Sondenspitze in einen Reagensbehälter, der eine Reagenslösung enthält, die ein Reagens eines zweiten Antikörpers enthält, das mit einem ersten Element eines Bindungspaares konjugiert ist, um das Reagens an den Analyten zu binden;
- (d) Eintauchen der Sondenspitze in einen ersten Waschbehälter, der eine erste Waschlösung enthält, um die Sondenspitze zu waschen;
- 10 (e) Eintauchen der Sondenspitze in einen Amplifikationsbehälter, der Folgendes enthält: eine Amplifikationslösung, die ein Polymer umfasst, das mit wenigstens 5 Molekülen eines zweiten Elements des Bindungspaares konjugiert ist, und wenigstens 25 Lumineszenzmarker, um einen Immunkomplex des Analyten, des ersten Antikörpers, des zweiten Antikörpers und des ersten und des zweiten Elements des Bindungspaares an der Sondenspitze auszubilden, wobei das Polymer verzweigt ist und eine Molekülmasse von wenigstens 1 Million Dalton aufweist und wobei die Lumineszenzmarker eine Molekülmasse von weniger als 2.000 Dalton aufweisen;
- 15 (f) Eintauchen der Sondenspitze in einen zweiten Waschbehälter, der eine zweite Waschlösung enthält, um die Sondenspitze zu waschen;
- (g) Wiederholen der Schritte (c) bis (f) 1-10 Mal, und
- 20 (h) Nachweisen des ausgebildeten Immunkomplexes durch Messen des Lumineszenzsignals an der Sondenspitze; wobei der erste Antikörper und der zweite Antikörper Antikörper gegen den Analyten sind.
2. Verfahren nach Anspruch 1, wobei die Spitzenerfläche \leq etwa 2 mm ist.
3. Verfahren nach Anspruch 1, wobei das Bindungspaar ein Hapten und sein Antikörper, ein Ligand und sein Rezeptor, komplementäre Stränge von Nucleinsäuren oder Lektin und Kohlenhydrate ist.
- 25 4. Verfahren nach Anspruch 3, wobei das Bindungspaar Biotin und Streptavidin, Biotin und Avidin, Biotin und Neutra-vidin, Fluorescein und Antifluorescein, Digioxygenin/Antidigioxygenin oder DNP und Anti-DNP ist.
- 30 5. Verfahren nach Anspruch 4, wobei das erste Element des Bindungspaares Biotin ist und das zweite Element des Bindungspaares Streptavidin ist.
6. Verfahren nach Anspruch 1, wobei das Polymer ein Polysaccharid, ein Polynukleotid, ein Dendrimer, ein Polyole oder Polyethylenglycol ist.
- 35 7. Verfahren nach Anspruch 1, wobei das Polymer vernetztes Ficoll ist.
8. Verfahren nach Anspruch 1, wobei der Lumineszenzmarker ein fluoreszenter Farbstoff ist, ausgewählt aus der Gruppe bestehend aus Cyanin, Kumarin, Xanthen und einem Derivat davon.
- 40 9. Verfahren nach Anspruch 1, wobei der Lumineszenzmarker ein chemilumineszentes Molekül ist, ausgewählt aus der Gruppe bestehend aus Ruthenium(II)tris-bipyridin, Luminol, Acridiniumester und Hemin.
10. Verfahren nach Anspruch 1, wobei das Polymer mit 5-50 Bindungsmolekülen und mit 25-100 Lumineszenzmolekülen konjugiert ist.
- 45 11. Verfahren nach Anspruch 1, wobei das Polymer vernetztes Ficoll ist und mit 20-30 Streptavidin und 40-90 Cy 5 konjugiert ist.
- 50 12. Verfahren nach Anspruch 1, wobei die Schritte (c) bis (f) folgendermaßen wiederholt werden:
- (i) 1-5 Mal; oder
- (ii) 2-3 Mal.
- 55

Revendications

1. Méthode de détection d'un analyte dans un échantillon liquide, comprenant les étapes qui consistent à :

EP 2 699 906 B1

(a) obtenir une sonde ayant un premier anticorps immobilisé sur la pointe de la sonde, le diamètre de la surface de la pointe étant ≤ 5 mm ;

(b) tremper la pointe de la sonde dans une cuve à échantillon contenant une solution échantillon qui présente un analyte pour lier l'analyte au premier anticorps sur la pointe de la sonde ;

(c) tremper la pointe de la sonde dans une cuve à réactif contenant une solution réactive qui comprend un réactif correspondant à un deuxième anticorps conjugué à un premier membre d'une paire de liaison pour lier le réactif à l'analyte ;

(d) tremper la pointe de la sonde dans une première cuve de lavage contenant une première solution de lavage pour laver la pointe de la sonde ;

(e) tremper la pointe de la sonde dans une cuve d'amplification contenant une solution d'amplification qui comprend un polymère conjugué à au moins 5 molécules du deuxième membre de la paire de liaison et au moins 25 marqueurs luminescents pour former un immunocomplexe de l'analyte, du premier anticorps, du deuxième anticorps et des premier et deuxième membres de la paire de liaison sur la pointe de la sonde, où le polymère est ramifié et a un poids moléculaire d'au moins 1 million Daltons et où les marqueurs luminescents ont un poids moléculaire inférieur à 2 000 Daltons ;

(f) tremper la pointe de la sonde dans une deuxième cuve de lavage contenant une deuxième solution de lavage pour laver la pointe de la sonde ;

(g) répéter les étapes (c) à (f) 1-10 fois, et

(h) détecter l'immunocomplexe formé en mesurant le signal luminescent sur la pointe de la sonde ; où le premier anticorps et le deuxième anticorps sont des anticorps dirigés contre l'analyte.

2. Méthode selon la revendication 1, où la surface de la pointe est ≤ 2 mm environ.

3. Méthode selon la revendication 1, où la paire de liaison est un haptène et son anticorps, un ligand et son récepteur, des brins d'acides nucléiques complémentaires ou une lectine et des hydrates de carbone.

4. Méthode selon la revendication 3, où la paire de liaison est une biotine et la streptavidine, une biotine et l'avidine, une biotine et la neutravidine, une fluorescéine et un anticorps anti-fluorescéine, une digoxigénine et un anticorps anti-digoxigénine ou une DNP et un anticorps anti-DNP.

5. Méthode selon la revendication 4, où le premier membre de la paire de liaison est une biotine et le deuxième membre de la paire de liaison est la streptavidine.

6. Méthode selon la revendication 1, où le polymère est un polysaccharide, un polynucléotide, un dendrimère, un polyol ou un polyéthylène glycol.

7. Méthode selon la revendication 1, où le polymère est un Ficoll réticulé.

8. Méthode selon la revendication 1, où le marqueur luminescent est un pigment fluorescent sélectionné dans le groupe consistant en les suivants : cyanine, coumarine, xanthène et dérivé de ceux-ci.

9. Méthode selon la revendication 1, où le marqueur luminescent est une molécule chimioluminescente sélectionnée dans le groupe consistant en les suivantes : ruthénium(II)-Tris(bipyridine), luminol, ester d'acridinium et hémine.


10. Méthode selon la revendication 1, où le polymère est conjugué à 5-50 molécules de liaison et 25-100 molécules luminescentes.


11. Méthode selon la revendication 1, où le polymère est un Ficoll réticulé qui est conjugué à 20-30 molécules de streptavidine et 40-90 molécules de Cy 5.

12. Méthode selon la revendication 1, où les étapes (c) à (f) sont répétées :

(i) 1-5 fois; ou

(ii) 2-3 fois.





Probe Transfer




FIG. 4

Crosslinked Ficoll-SPDP Preparation




FIG. 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5268486 A [0003]
- US 20010312105 A [0005] [0062]
- WO 2010101931 A2 [0005]
- WO 8602929 A [0036]
- EP 063879 A [0036]
- EP 2009996 A [0036]
- US 20110312105 A [0040]

Non-patent literature cited in the description

- **MUJUMDAR et al.** *Bioconjugate Chemistry*, 1993, vol. 4, 105-111 [0003]
- **SOUTHWICK et al.** *Cytometry*, 1990, vol. 11, 418-430 [0003]
- **LEARY et al.** *Proc. Natl. Acad. Sci. USA*, 1983, vol. 80, 4045-4049 [0036]
- **LANGER et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 6633-6637 [0036]
- **BLACKBURN et al.** *Clin. Chem.*, 1991, vol. 37, 1534-1539 [0042]

专利名称(译)	发光聚合物循环扩增		
公开(公告)号	EP2699906A2	公开(公告)日	2014-02-26
申请号	EP2012773652	申请日	2012-04-16
[标]申请(专利权)人(译)	万迈医疗仪器有限公司		
申请(专利权)人(译)	ACCESS医疗系统, LTD.		
当前申请(专利权)人(译)	ACCESS医疗系统, LTD.		
[标]发明人	ZUK ROBERT F TAN HONG		
发明人	ZUK, ROBERT F. TAN, HONG		
IPC分类号	G01N33/53 G01N33/52 G01N33/533 G01N33/543		
CPC分类号	G01N33/54393 G01N33/533 G01N21/76 G01N27/3277 G01N33/5306 G01N33/5438 G01N33/553 G01N2021/757		
代理机构(译)	MOORE, MICHAEL RICHARD		
优先权	61/477171 2011-04-20 US		
其他公开文献	EP2699906A4 EP2699906B1		
外部链接	Espacenet		

摘要(译)

本发明涉及用于以高灵敏度检测液体样品中的分析物的发光免疫分析方法。本发明提供了一种独特的组合：(i) 使用具有小传感面积的探针来结合分析物分子，(ii) 使用与多个结合分子和多个发光标记物共轭的高分子量支链聚合物，以及(iii) 循环形成具有免疫复合物的探针1-10次回到试剂容器和扩增容器，并重复与试剂和扩增聚合物的反应，以提高检测水平的灵敏度。对于每个循环，发光信号都会比噪声明显增加。